Drugs / gp209-2M
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00019487 | Nov 1998 → May 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp209-2M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019487 ↗ |
| Modality | Peptide | “gp209-2M peptide” NCT00019487 ↗ |
| Route | Subcutaneous | “An additional cohort of 8 patients receives gp209-2M peptide in Montanide ISA-51 subcutaneously in 2 different sites” NCT00019487 ↗ |